Dashboard

Author picture

Test case

Patient info
Biological Sex: Female
Year of birth: 1960
Case details
Diagnosis: Chronic lymphocytic leukemia
Date of diagnosis:
January
2022
Type of current or last treatment: Acalabrutinib - monotherapy
Description of other type of current or last treatment: test
Doses of current or last treatment:
- Alemtuzumab:500mg
Date of current or last treatment: ​ January
2023
Is the treatment ongoing? Yes
Date of treatment interruption: ​ January
2023
Current or last line of treatment: 1
Karyotype result before current treatment: test
Concomitant medication(s): test
Current adverse event: test
Previous adverse events: test
Comorbidities: test
Grade of current adverse event: 2
Cycle of the adverse event initiation: 3
Days since the adverse event onset: 2
Before current treatment
IGHV gene status: Mutated
del17p: Positive
TP53 mutation status: Present
Case description:

test

Case ID:
2980
Raised by:
inab.tester2@certh.gr
Date & Time:
2024-11-13 16:01:07
Topic: Adverse events after dose reduction
Author picture

Test case

test

Internal Board Messages
No reply yet.
Write your opinion:
We will reply soon.
Write your opinion:
Ticket ID:
2980
Raised by:
Date & Time:
2024-11-13 16:01:07
Subject: Adverse events after dose reduction
Status: Unassigned
Picture of inab.tester2@certh.gr

Test case

test

We will reply soon.
Ticket ID:
2980
Raised by:
inab.tester2@certh.gr
Date & Time:
2024-11-13 16:01:07
Subject:
Adverse events after dose reduction
Status:
Unassigned